Literature Review on the Immunogenicity of Herpes Zoster Vaccines

Herpes zoster is an acute viral infection caused by reactivation of varicella-zoster virus (VZV). LZV, a live, attenuated vaccine for zoster has been available in Canada for many years. A new subunit recombinant zoster vaccine (RZV) named Shingrix was approved in Canada in October 2017. This zoster vaccine immunogenicity review was done to have a comprehensive understanding of the immunogenicity of both live and subunit vaccines.

Data and Resources

Additional Info

Field	Value
Last Updated	April 17, 2026, 19:08 (UTC)
Created	April 17, 2026, 19:08 (UTC)
criticality_level	[]
geographic_scope	[]
open_canada_collection	publication
open_canada_date_published	2019-02-11 00:00:00
open_canada_keywords	{"fr": ["Zona", "infection", "virale", "aiguë", "réactivation", "virus varicelle-zona", "VVZ", "VVVCZ", "vaccin", "virus", "vivant", "atténué", "offert", "Canada", "nombreuses", "nouveau vaccin", "recombinant", "sous-unitaire", "VRZ", "Shingrix", "Canada", "2017", "immunogénicité"], "en": ["Herpes", "zoster", "acute", "viral", "infection", "reactivation", "varicella-zoster virus", "VZV", "LZV", "live", "attenuated", "vaccine", "zoster", "Canada", "subunit", "recombinant zoster vaccine", "RZV", "Shingrix", "Canada", "2017", "zoster vaccine", "immunogenicity", "live", "subunit vaccines"]}
open_canada_subject	["health_and_safety"]
sensitivity_level	unrestricted
title_fr	Revue de la littérature sur l’immunogénicité des vaccins contre le zona
update_frequency	unknown